drugset / Trial / NCT06805266

Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

NCT06805266

Phase 4 Not yet recruiting 40 enrolled Marianna Amboni
NaSingle-groupOpen-labelTreatment

Summary

The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate/severe FOG not responsive to dopaminergic treatment in patients with PD with depressive symptoms.

Timeline

Start
2025-02
Primary completion
2026-12
Completion
2027-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg